Vaccine: Fluarix
Company: GlaxoSmithKline
Approval Date: Fluarix
Protects Against: Influenza

GlaxoSmithKline ($GSK) ramped up vaccine production with the development of a $300 million vaccine manufacturing facility in Pennsylvania in 2009. Not to be confused with GSK's newest flu vaccine, Fluarix Quadrivalent, Fluarix protects against three flu strains and is approved for those age 3 and older. Fluarix and FluLaval together reached £230 million ($369.9 million) worldwide in 2011. Sales of the pair grew specifically in the United States, showing a 25% jump from the year before to £132 million ($212.2 million). Not bad for a vaccine first approved in 2005.

For more:
GSK unveils $300M vax facility for U.S. market push
GSK kickstarts global trial for seasonal flu vax
Agency OKs Fluarix, opening spigot of vaccine supplies


Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.